NO20013554D0 - Antikonvulsive derivater som kan benyttes ved behandling av klusterhodepiner - Google Patents

Antikonvulsive derivater som kan benyttes ved behandling av klusterhodepiner

Info

Publication number
NO20013554D0
NO20013554D0 NO20013554A NO20013554A NO20013554D0 NO 20013554 D0 NO20013554 D0 NO 20013554D0 NO 20013554 A NO20013554 A NO 20013554A NO 20013554 A NO20013554 A NO 20013554A NO 20013554 D0 NO20013554 D0 NO 20013554D0
Authority
NO
Norway
Prior art keywords
treatment
cluster headaches
anticonvulsant derivatives
anticonvulsant
derivatives
Prior art date
Application number
NO20013554A
Other languages
English (en)
Norwegian (no)
Other versions
NO20013554L (no
Inventor
Enrique Carrazana
Steve D Wheeler
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of NO20013554D0 publication Critical patent/NO20013554D0/no
Publication of NO20013554L publication Critical patent/NO20013554L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
NO20013554A 1999-01-19 2001-07-18 Antikonvulsive derivater som kan benyttes ved behandling av klusterhodepiner NO20013554L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11638899P 1999-01-19 1999-01-19
PCT/US2000/000919 WO2000042996A2 (en) 1999-01-19 2000-01-13 Use of anticonvulsant derivatives for treating cluster headaches

Publications (2)

Publication Number Publication Date
NO20013554D0 true NO20013554D0 (no) 2001-07-18
NO20013554L NO20013554L (no) 2001-07-18

Family

ID=22366884

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013554A NO20013554L (no) 1999-01-19 2001-07-18 Antikonvulsive derivater som kan benyttes ved behandling av klusterhodepiner

Country Status (24)

Country Link
US (1) US6319903B1 (xx)
EP (1) EP1143967B1 (xx)
JP (1) JP2002535270A (xx)
KR (1) KR100653326B1 (xx)
CN (1) CN1182845C (xx)
AT (1) ATE279921T1 (xx)
AU (1) AU771388B2 (xx)
BR (1) BR0008176A (xx)
CA (1) CA2359541C (xx)
CZ (1) CZ20012620A3 (xx)
DE (1) DE60015070T2 (xx)
DK (1) DK1143967T3 (xx)
ES (1) ES2228465T3 (xx)
HU (1) HUP0105154A3 (xx)
IL (2) IL144406A0 (xx)
MX (1) MXPA01007350A (xx)
MY (1) MY121486A (xx)
NO (1) NO20013554L (xx)
NZ (1) NZ513115A (xx)
PT (1) PT1143967E (xx)
TR (1) TR200102711T2 (xx)
TW (1) TWI248360B (xx)
WO (1) WO2000042996A2 (xx)
ZA (1) ZA200106786B (xx)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
AU8830801A (en) * 2000-08-17 2002-02-25 Teva Pharma Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
UA81110C2 (en) * 2002-02-26 2007-12-10 Ortho Mcneil Pharm Inc Co-therapy with a topiramate and triptan for the treatment of migraine or nausea, photophobia, phonophobia associated with migraine
EP1494998A2 (en) 2002-03-01 2005-01-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
WO2003080072A1 (en) * 2002-03-18 2003-10-02 Cady Roger K Preemptive prophylaxis of migraine
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CA2489984A1 (en) 2002-06-21 2003-12-31 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20040176463A1 (en) * 2003-02-05 2004-09-09 Daniella Licht Immediate release formulation of n-(2-propylpentanoyl)glycinamide
WO2004071421A2 (en) * 2003-02-05 2004-08-26 Teva Pharmaceutical Industries Ltd. Sustained release formulation of n-(2-propylpentanoyl) glycinamide and related compounds
US6949518B1 (en) 2003-06-25 2005-09-27 Pao-Hsien Chu Methods for treating macular degeneration with topiramate
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MX2007002309A (es) * 2004-08-24 2007-10-08 Johnson & Johnson Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos.
US20060233892A1 (en) * 2005-04-19 2006-10-19 Curt Hendrix Topiramate compositions for treatment of headache
US20110117070A1 (en) * 2005-04-19 2011-05-19 Aurora Sheena K Compositions and methods for treating headache
JP2008545650A (ja) 2005-05-20 2008-12-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ スルファミド誘導体の製造方法
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8492431B2 (en) * 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
TW200812573A (en) * 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
US9744137B2 (en) 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
WO2008061226A2 (en) 2006-11-17 2008-05-22 Supernus Pharmaceuticals Inc. Sustained-release formulations of topiramate
CN102218044A (zh) 2006-12-04 2011-10-19 苏佩努斯制药公司 托吡酯的增强的立即释放制剂
US20090076128A1 (en) * 2007-09-15 2009-03-19 Protia Llc Deuterium-enriched topiramate
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
MX2011000090A (es) 2008-06-23 2011-03-02 Janssen Pharmaceutica Nv Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]diox in-2-ilmetil)sulfamida.
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CN102579367B (zh) 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 托吡酯缓释药物组合物、其制备方法及用途
US9457008B2 (en) 2012-03-23 2016-10-04 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China Joint product comprising synephrine and topiramate
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US20220016074A1 (en) 2018-11-21 2022-01-20 Rosemont Pharmaceuticals Limited Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US5998380A (en) * 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
ES2187795T3 (es) * 1996-10-08 2003-06-16 Ortho Mcneil Pharm Inc Derivados de anticonvulsivos utiles en el tratamiento del dolor neuropatico.

Also Published As

Publication number Publication date
CA2359541C (en) 2005-06-21
DK1143967T3 (da) 2005-01-10
BR0008176A (pt) 2001-11-06
WO2000042996A3 (en) 2000-12-07
CN1352555A (zh) 2002-06-05
AU2726800A (en) 2000-08-07
WO2000042996A2 (en) 2000-07-27
KR100653326B1 (ko) 2006-12-04
JP2002535270A (ja) 2002-10-22
CZ20012620A3 (cs) 2002-09-11
TR200102711T2 (tr) 2001-12-21
NZ513115A (en) 2004-11-26
KR20010101595A (ko) 2001-11-14
CN1182845C (zh) 2005-01-05
ATE279921T1 (de) 2004-11-15
HUP0105154A3 (en) 2004-10-28
PT1143967E (pt) 2005-01-31
TWI248360B (en) 2006-02-01
HUP0105154A2 (hu) 2002-04-29
IL144406A0 (en) 2002-05-23
DE60015070T2 (de) 2006-01-05
ZA200106786B (en) 2002-11-18
ES2228465T3 (es) 2005-04-16
MXPA01007350A (es) 2003-06-06
MY121486A (en) 2006-01-28
IL144406A (en) 2006-08-20
EP1143967B1 (en) 2004-10-20
US6319903B1 (en) 2001-11-20
DE60015070D1 (de) 2004-11-25
CA2359541A1 (en) 2000-07-27
EP1143967A2 (en) 2001-10-17
NO20013554L (no) 2001-07-18
AU771388B2 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
NO20013554L (no) Antikonvulsive derivater som kan benyttes ved behandling av klusterhodepiner
TR200103216T2 (tr) Pirimidinon bileşimleri
DE60022917D1 (de) Reboxetin zur Behandlung von Migränekopfschmerzen
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
MY138285A (en) Fab i inhibitors
IL144643A0 (en) Jak-3 inhibitors for treating allergic disorders
HK1050860A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
AU2002231150A1 (en) Method and apparatus for improving the efficiency of cache memories using chained metrics
NO20022245D0 (no) Onkolyttiske kombinasjoner for behandling av cancer
MXPA03004517A (es) Metodos que emplean y composiciones que contienen fosfolipidos oxidados definidos para la prevencion y tratamiento de la arteriosclerosis.
NO991619L (no) Anvendelse av en H+, K+-ATPase-inhibitor i behandlingen av nesepolypper
AU2001266838A1 (en) Inhibitors of matriptase for the treatment of cancer
NO20002804D0 (no) Konjugater som kan anvendes ved behandling av prostatakreft
DK0808307T3 (da) Bicykliske isothiourinstofderivater, som kan anvendes ved terapi
AU2001265186A1 (en) Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions
TR200103125T2 (tr) Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri.
NO334788B2 (no) Fremgangsmåte for behandling av søvnløshet
NO20012423D0 (no) Antikonvulsjonsmiddelderivater som er nyttige ved behandling av posttraumatiske stresslidelser
MXPA03004017A (es) Metodo para el tratamiento de inflamacion.
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
DE60125035D1 (de) Behandlung von plasmid-haltigen lösungen
BR0008791A (pt) Derivados anticonvulsivos, úteis no tratamento de tremor essencial
DK1500396T3 (da) Reboxetin til behandling af migrænehovedpiner
AU2002256967A1 (en) Treating or reducing the risk of cardiovascular disease
WO2002047672A3 (en) Treatment of cystic fibrosis with alkalinizing agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application